Trial Profile

Development and Validation of New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma in CYP3A5 Expressors and Non-Expressors

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Liver transplant rejection; Renal transplant rejection
Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

05 Apr 2022 Planned number of patients changed from 121 to 380.
05 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 May 2023.
05 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com